Doxorubicin Hydrochloride NDC 68001-703

NDC codes

FDA NDC Directory

Product NDC (as listed)68001-703Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68001-0703Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68001-703-36	68001070336	1 VIAL, SINGLE-DOSE in 1 CARTON (68001-703-36) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 2, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Doxorubicin Hydrochloride
Generic name (nonproprietary): doxorubicin hydrochloride
Active ingredients: Doxorubicin hydrochloride — 2 mg/mL
Dosage form: Injectable, Liposomal
Route: Intravenous
Labeler: BluePoint Laboratories
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212299
Marketing start: Apr 2, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Anthracyclines (Chemical structure)Topoisomerase Inhibitors (Mechanism)
Identifiers: Product ID 68001-703_4dff7ee8-c0a2-c78d-e063-6394a90a79e8SPL ID 4dff7ee8-c0a2-c78d-e063-6394a90a79e8SPL set ID ada390ce-50ea-4de5-be58-5b03caf33c23RxCUI 1790115, 1790127UNII 82F2G7BL4E
Pharmacologic class: Anthracycline Topoisomerase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N468001070336 followed by a unit qualifier and the quantity

Package 68001-0703-36. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi's Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi's Sarcoma Doxorubicin hydro…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212299

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212299
Product	Strength	Form · route	Labeler	Product NDC
Doxorubicin Hydrochloride	Doxorubicin hydrochloride 2 mg/mL	Injectable, LiposomalIntravenous	BluePoint Laboratories	68001-704
Doxorubicin Hydrochloride	Doxorubicin hydrochloride 2 mg/mL	Injectable, LiposomalIntravenous	Zydus Lifesciences Limited	49315-008
Doxorubicin Hydrochloride	Doxorubicin hydrochloride 2 mg/mL	Injectable, LiposomalIntravenous	Zydus Lifesciences Limited	49315-009
Doxorubicin Hydrochloride	Doxorubicin hydrochloride 2 mg/mL	Injectable, LiposomalIntravenous	Zydus Pharmaceuticals USA Inc.	70710-1530
Doxorubicin Hydrochloride	Doxorubicin hydrochloride 2 mg/mL	Injectable, LiposomalIntravenous	Zydus Pharmaceuticals USA Inc.	70710-1531